 The review shows the development in the prophylactics and therapy of methicillin (multi)-resistant Staphylococcus aureus (MRSA) and the lately emergenced vancomycin-resistant Staphylococcus aureus (VRSA) strains the lately emergenced. A state of the art decontamination and isolation guideline with a special emphasis on critical care patients is given. Also the article reviews the currently used antibiotic drugs for local and systemic treatment of MRSA infection. The most important systemic administered drugs are discussed with a focus on glycopeptides. Quinupristin/ Dalfopristin (Synercid, RP 59500) as a substance, which is currently being clinically investigated and is close to its registration, is also introduced and quoted.  
